Recent 8-K filings for BLLN
Highest-materiality recent filing
BillionToOne Q1 revenue $108.4M (+84% YoY), raises FY 2026 guidance to $450M-$465M
- Net income $18.0M ($0.34 diluted) vs loss of $4.0M (-$0.39) in Q1 2025.
- Gross margin improved to 73% from 64% YoY; operating income $17.8M vs loss $2.3M.
-
BillionToOne Q2 revenue $109.4M (+64% YoY); net income $8.1M; reiterates FY guidance $450-465M
Revenue $109.4M (+64% YoY); prenatal $94.2M (+55%), oncology $13.7M (+176%).
-
BillionToOne enters 12-year lease for 62,659 sq ft oncology lab; base rent $46.7M
Leased 62,659 sq ft office and lab space at 3260 Whipple Road, Union City, CA on June 23, 2026.
-
BillionToOne stockholders elect Atay and Rai as Class I directors; ratify PwC as auditor
Oguzhan Atay elected with 76,387,783 votes for; Akshay Rai with 76,297,791 for (both Class I directors).
-
BillionToOne Q1 revenue $108.4M (+84% YoY), raises FY 2026 guidance to $450M-$465M
Net income $18.0M ($0.34 diluted) vs loss of $4.0M (-$0.39) in Q1 2025.
-
BillionToOne Q4 rev $96.1M (+113% YoY); net income $4.4M; raises FY26 guidance
Q4 revenue $96.1M (+113% YoY); net income $4.4M ($0.11 diluted) vs loss of $11.5M.
-
BillionToOne guides FY2026 revenue $415-430M, up ~43% YoY; positive operating income
Reiterated FY2025 revenue guidance of $293M-$299M with positive GAAP operating income.
-
BillionToOne Q3 revenue $83.5M (+117% YoY); guides FY2025 revenue $293-299M
Q3 total revenue $83.5M (+117% YoY); prenatal revenue $74.1M (+102%), oncology $8.7M (7.6x YoY).
-
BillionToOne closes IPO of 5.23M shares at $60; gross proceeds ~$314M
Closed IPO on Nov 7, 2025, selling 5,233,765 shares (including full underwriter option) at $60.00 per share.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.78 · Most common event earnings